Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Micron Technology, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.59 (market cap $39.89B), while Micron Technology, Inc. trades at $938.36 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 27.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Micron Technology, Inc. pays a 0.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MU | |
|---|---|---|
Market Cap | $39.89B | $1.11T |
Sector | Health | Technology |
52-Week High | $491.22 | $1.21K |
52-Week Low | $278.09 | $104.88 |
Enterprise Value | $38.15B | $1.09T |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Micron Technology (MU) trades at $979.30, down 1.24% on the day, with strong technical support near $974 and bullish moving average signals. The company demonstrates exceptional fundamental strength with Q1 2026 EPS of $25.11 beating expectations by 20%, robust 55.91% net income margins, and accelerating revenue growth from $37.38B in 2025 to projected $90.3B in 2026. Recent news highlights the company's $250 billion AI memory investment and leadership in the semiconductor shortage cycle.
Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 57% upside. Key opportunities include AI memory demand and humanoid robotics growth, while risks involve cyclical semiconductor exposure and competitive pressure from SK Hynix's Nasdaq debut. The stock presents a compelling growth story with strong earnings momentum and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
